Catalio Capital Management
VC Fund
Baltimore, United States
Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.
- Total investments:
- 145
- Last investment:
- Lead investor:
- 30%
- Fund size:
- $16M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Catalio Capital Management invests in
Stages Catalio Capital Management invests in
Countries Catalio Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $9.7M–$150M
- Series B
- $26M–$130M
Investment Focus
Industry
- Biotechnology 60 (41%)
- Health Care 41 (28%)
- Life Science 23 (16%)
- Medical 21 (14%)
- Therapeutics 20 (14%)
Stage
- Series A 25 (17%)
- Series B 24 (17%)
- Funding Round 16 (11%)
- Series C 12 (8%)
- Series D 9 (6%)
Country
- United States 68 (47%)
- Switzerland 3 (2%)
- Israel 2 (1%)
- France 1 (1%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ben Snedeker
Partner and Co-Head Public Equities
|
Partner and Co-Head Public Equities | Total investments: 0 | Find email | |
George Petrocheilos
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 10 | Find email | |
Isaac Ro
Partner
|
Partner | Total investments: 3 | Find email | |
Jacob Vogelstein
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 11 | Find email | |
Kenan Turnacioglu
General Partner
|
General Partner | Total investments: 6 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $65.5M / Series B / Sep 03, 2026 | ||
| Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $70M / Series C / Jul 31, 2026 | ||
| Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | ||
| Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M / Post-IPO Equity / Jul 27, 2026 | ||
| Flourish Labs is a research and development company that combines certified humans, technology, and AI to provide every employee with a dedicated coach. The company builds AI-powered platforms for peer mental health support, focused on making mental health care accessible. | $500M / Series A / Jun 04, 2026 | ||
| 9amHealth is a virtual healthcare company focused on managing chronic cardiometabolic conditions such as diabetes, obesity, high blood pressure, and high cholesterol. The platform connects patients with licensed healthcare providers, pharmacists, nutritionists, prescription delivery services, and at-home laboratory testing through a digital caremodel. Its services include personalized treatment plans, medication management, ongoing monitoring, and remote consultations designed to support long-term condition management. The company also works with employers, health plans, and pharmacy benefit managers to provide healthcare support programs for individuals living with chronic illnesses. 9am.health’s care approach combines medical treatment, behavioral support, and digital tools to help patients access healthcare services remotely and manage their conditions more consistently. | $26M / Series B / May 12, 2026 | ||
| Thea is an AI-powered skincare and dermatology app that gives personalized skincare advice, product recommendations, and treatment guidance using computer vision and chat-based assistance. | $4M / Pre-Seed / May 08, 2026 | ||
| Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M / Convertible Note / Mar 17, 2026 | ||
| Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression.Compass Pathways conducts clinical trials and research toassess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression. | $200M / Post-IPO Equity / Feb 26, 2026 | ||
| ProSomnus designs and manufactures intraoral devices designed to help dentists get patients into therapy faster, with greater comfort, and treatment effectiveness. Its flagship products are the ProSomnus [IA] and MicrO2 Sleep, and Snore Devices. Its devices are the first, precision oral appliance therapy devices designed to enhance compliance,mitigate side effects, and enable dentists to achieve excellent patient experiences and outcomes. The company was founded in 2016 and is headquartered in Pleasanton, California. | $38M / Venture - Series Unknown / Feb 18, 2026 | ||
| See all 145 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Catalio Capital Management invest in?
Catalio Capital Management invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 145 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Catalio Capital Management's check size?
Catalio Capital Management typically joins rounds of $9.7M–$150M at Series A and $26M–$130M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Catalio Capital Management participates in.
How do I contact Catalio Capital Management?
Public channels for Catalio Capital Management include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Catalio Capital Management?
The team at Catalio Capital Management includes Ben Snedeker (Partner and Co-Head Public Equities), George Petrocheilos (Co-Founder & Managing Partner) and Isaac Ro (Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
